BMC Research Notes · 2017 · 17 citations · 9 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPharmacovigilanceCardiovascular Drug SafetyDrug Safety MonitoringGeneric Drug EvaluationLipid-lowering TherapyBrand-to-generic ComparisonCohort Study InvestigationEssential Medicines AvailabilityLipid-lowering Drug EfficacyLipid-lowering Drug SafetyLow-density Lipoprotein Cholesterol LoweringPlasma Cholesterol LevelsTriglyceride Lowering
BACKGROUND: In a world of ever increasing health care costs, generic drugs represent a major opportunity to ensure access to essential medicines for people who otherwise would be unable to afford them. However, some clinicians and patients are still questioning the safety and effectiveness of generic formulations compared to the proprietary drugs necessitating further systematic research analyzing the generic drugs' efficacy. Our objective was to compare the lipid lowering effects of generic and branded atorvastatin. METHODS: ) to generic atorvastatin (atorvastatin calcium from Ranbaxy Laboratories, Inc.). We also investigated if there was any difference in the effectiveness of both atorvastatin formulations in various ethnic groups. RESULTS: 266 patients were included in this study. When comparing the median values we found no statistically significant differences (Wilcoxon signed-rank test; p < 0.05) between proprietary and generic atorvastatin in lowering total cholesterol (4.60 mmol/l pre-transition vs. 4.50 mmol/l post-transition; p = 0.583), LDL-cholesterol (2.42 mmol/l vs. 2.41 mmol/l; p = 0.923) and triglycerides (1.50 mmol/l vs. 1.50 mmol/l; p = 0.513). While there was a statistically significant (p = 0.009) difference in HDL-cholesterol levels favouring proprietary atorvastatin, the extent of this change (1.26 mmol/l vs. 1.25 mmol/l) was deemed not to be clinically relevant. There was no statistically significant difference when analyzing the effects on various ethnic groups. CONCLUSIONS: Substituting proprietary atorvastatin for its generic formulation atorvastatin calcium does not result in a less effective management of hyperlipidemia. Our findings lend support to the approach of lowering health care costs by switching patients from branded drugs to their less expensive generic analogues.
9
Physician Perceptions About Generic Drugs
William H. Shrank, Joshua N. Liberman, Michael A. Fischer et al. · Annals of Pharmacotherapy · 2011 · 193 citations
Generic Atorvastatin and Health Care Costs
Cynthia A. Jackevicius, Mindy M. Chou, Joseph S. Ross et al. · New England Journal of Medicine · 2011 · 68 citations · Full text
Cynthia A. Jackevicius, Jack V. Tu, Harlan M. Krumholz et al. · Journal of the American Heart Association · 2016 · 36 citations · Full text
Sang‐Hyun Kim, Kyungil Park, Soon-Joon Hong et al. · Clinical Therapeutics · 2010 · 30 citations